Clinical trial matching: the frustration of matching patients to cancer research begins with data issues — and can end with artificial intelligence
If you work in oncology or cancer clinical trial coordination in the US, you already know the numbers don’t always work in your or your patients’ favor.
Bobbi Coluni, offering management for the payer market at IBM Watson Health shares her personal experience with the complexity of navigating healthcare benefits.
Novant Health UVA Health System Culpeper Medical Center analyzed data to tackle their #1 cause of readmissions: sepsis.
We at IBM have a lot to be proud of, including our pioneering work with Watson Health. Unfortunately, some media reports, including an August 11th story published by The Wall Street Journal, distort and ignore facts when suggesting IBM has not made “enough” progress on bringing the benefits of AI to healthcare.
The Connecticut Children’s Medical Center revenue cycle and clinical teams worked with Simpler® Consulting, part of IBM Watson Health, to address shortcomings in their processes, resulting in fewer claim denials and improved patient experience.
I would like to provide an update on Watson Health and address a few misperceptions. If you only read certain media reports recently, you would have an incomplete and inaccurate perspective, especially as it relates to our Watson for Oncology product.
In this infographic, we’ve summarized other findings from a survey of 300+ healthcare professionals who responded to describe the efforts they’re undertaking and the barriers they’re experiencing.
This research brief includes highlights from a 2017 survey designed to seek opinions on the current climate for US healthcare executives.
As healthcare providers transition to value-based care models, PHM plays a critical role in financial risk arrangements with public and private payers.